Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should ...

As of Thursday, October 08, Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 10.42%, which has investors ...

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous ...

ARK Invest sold Twist Bioscience shares and bought Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte stock on ...

Recursion Pharmaceuticals (RXRX) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of ...

Nvidia just invested millions into Recursion Pharmaceuticals, bolstering AI integration in biotech but also presenting risks for RXRX stock.More From InvestorPlace Buy This $5 Stock BEFORE This Apple ...

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...